文献速递临床生化临床血液与体液质量管理与危急值

基于凝血酶原激活剂的下一代快速血清管技术:从正常样本快速制备高质量血清

Next-generation rapid serum tube technology using prothrombin activator coagulant: fast, high-quality serum from normal samples.
PubMed 文献 · Clin Chem Lab Med · 2019-01-01

本研究描述了一种在采血管中添加蛇毒凝血酶原激活剂复合物(OsPA)以快速制备高质量血清的新方法。通过血浆凝固试验、血栓弹力图和凝血酶生成试验评估凝血效果,并在生化与免疫分析仪上测定血清分析物。结果显示OsPA在临床环境中对新鲜全血具有强凝血活性,能加快凝血速度并生成更坚实的血凝块,且不干扰常用生化分析物的测定。

要点

  • OsPA可加速全血凝固并生成更坚实的血凝块。
  • OsPA制备的血清不干扰常用生化分析物测定。
  • 该技术有望缩短周转时间并标准化血清质量。

核心结论

  • OsPA添加于采血管可快速生成高质量血清,适用于正常个体,有助于缩短周转时间并实现标准化质量样本的准确分析物测定。

研究设计与样本

  • 采用Hyland-Clotek仪器进行血浆凝固试验,肉眼观察血凝,血栓弹力图测定凝血参数,发色底物S-2238检测凝血酶生成,并在生化与免疫分析仪上测定血清分析物,纤维蛋白原采用ELISA或Clauss法测定。

主要发现

  • OsPA对复钙枸橼酸血浆、复钙枸橼酸全血及临床环境中的新鲜全血均表现出强凝血活性。
  • 血栓弹力图显示OsPA改善了凝血速度并生成更坚实的血凝块。
  • 使用OsPA制备血清不干扰常用生化分析物的测定。
  • 其凝血机制涉及凝血初期接触血液中凝血酶原后爆发性产生凝血酶。

临床怎么用

  • 该技术可用于正常个体快速制备高质量血清,缩短检测周转时间并提高样本质量标准化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background Incomplete blood clotting or latent clotting in serum is a common laboratory problem, especially for patients on anticoagulant therapy or when serum tubes are centrifuged before clotting is completed. We describe a novel approach to producing high-quality serum using snake venom prothrombin activator complex (OsPA) as an additive in blood collection tubes for non-anticoagulated (normal) individuals. Methods Plasma clotting assays were performed using a Hyland-Clotek instrument. Blood clotting was visually observed, and thromboelastography was also performed to determine the important parameters of coagulation. Thrombin generation was assayed using the chromogenic substrate S-2238, and biochemical analytes in the serum were determined on chemistry and immunoassay analysers. Fibrinogen was determined by either ELISA or Clauss fibrinogen assay. Results We initially showed that OsPA had strong coagulation activity in clotting not only recalcified citrated plasma and recalcified citrated whole blood, but also fresh whole blood in a clinical setting. The use of TEG clearly showed improved speed of clotting and generation of a firmer clot. We also showed that the use of OsPA to produce serum did not interfere with the determination of commonly measured biochemical analytes. The underlying clotting mechanism involves a burst of thrombin production at the initial stages of the clotting process upon contact with prothrombin in blood. Conclusions These results demonstrate rapid generation of high-quality serum, contributing to faster turnaround times with standardised quality samples, for accurate analyte determinations in normal individuals.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Zhao KN, Dimeski G, de Jersey J, et al. Next-generation rapid serum tube technology using prothrombin activator coagulant: fast, high-quality serum from normal samples. Clin Chem Lab Med. 2019. PMID: 30267622. doi:10.1515/cclm-2018-0397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。